Consistent with our hypothesis, the first-generation EGFR-TKI erlotinib significantly reduced EGFR activation, expressed as pEGFR/EGFR ratio, in the two BRAF class 3–mutated cell lines (PDX-ADK-36 and ADK-14) and in the two EGFR-mutated (HCC-827 and PC-9) cell lines compared with the vehicle (P < .05), but not in the KRAS- (ADK-17), BRAF class 1–(HCC-364), and BRAF class 2–mutated (NCI-H1395) cell lines (Fig 3B). This evidence concerns the gene BRAF and hepatocellular carcinoma.